Nyrada, Inc. is a pre-clinical stage, drug discovery, and development company, which engages in the business of specializing in novel small molecule drugs to treat cardiovascular and neurological diseases. The firm also focuses on developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury. The company was founded by Graham Edmund Kelly on August 29, 2017 and is headquartered in Gordon, Australia.